Mylan N.V. disclosed Friday in a regulatory filing that a subsidiary was subpoenaed by the Department of Justice on Dec. 3, regarding its generic Doxycycline products. The drug maker said the subpoenas, from the DOJ's antitrust division, seek information related to the marketing, pricing and sale of the bacterial infection treatment, and any communications with competitors about such products. Mylan said it plans to cooperate fully with the DOJ's requests. The stock, which slipped 0.4% in light premarket trade, has lost 9.4% year to date, while the S&P 500 has eased 0.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
